<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129699</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP 5-12 / EORTC 08111</org_study_id>
    <secondary_id>2013-003156-21</secondary_id>
    <secondary_id>20080166</secondary_id>
    <secondary_id>SNCTP000000954</secondary_id>
    <nct_id>NCT02129699</nct_id>
  </id_info>
  <brief_title>Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy</brief_title>
  <acronym>SPLENDOUR</acronym>
  <official_title>A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how well the standard treatment (platinum-based
      doublet chemotherapy) in combination with denosumab works compared with the standard
      treatment alone in patients with a type of lung cancer called &quot;non small cell lung cancer&quot;
      (NSCLC) that has spread to other parts of the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational medicinal product denosumab is a protein (monoclonal antibody) that works
      to slow down bone destruction caused by cancer spreading to the bone (bone metastasis).
      Denosumab is used in adults with cancer to prevent serious complications caused by bone
      metastasis (e.g. fracture, pressure on the spinal cord or the need to receive radiation
      therapy or surgery). Results from one study in lung cancer patients with bone metastasis
      suggested that adding denosumab to the standard chemotherapy may lead to a possible survival
      benefit.

      All patients will receive standard chemotherapy consisting of a combination of platinum-based
      doublet agents plus gemcitabine or pemetrexed, depending on the nature of the lung cancer,
      every 3 weeks for about 3-4 months:

      Patients will be assigned to one of two groups, known as 'arms'.

      The treatment for each arm will be as follows:

      Arm A: 4 - 6 cycles of chemotherapy and best supportive care (including any bone protective
      agent except denosumab)

      Arm B: 4 - 6 cycles of chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4
      weeks until unacceptable toxicity, patient refusal or patient's death. After stop of
      first-line chemotherapy, denosumab must be continued every 3-4 weeks lifelong, regardless of
      tumour progression and concomitantly with subsequent lines of systemic treatment, as long as
      tolerable for the patient.

      Beyond primary analysis, all subjects randomised to ARM B and still benefitting from the drug
      will be offered denosumab at a dose of 120 mg s.c. until patient or physician elect to
      discontinue denosumab for any reason, and for a maximum of 2 years after the required number
      of events for the final analysis has been reached.

      A total of 1000 patients from centers in Europe, Switzerland and Israel are expected to be
      enrolled in this study over a period of 37 months.The study will take approximately 56 months
      to be completed
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 6, 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from the date of randomisation until death from any cause, assessed up to 56 months</time_frame>
    <description>Defined as time from the date of randomisation until death from any cause. Patients who are still alive at last contact are censored at the date of last follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) based on RECIST 1.1</measure>
    <time_frame>Time from date of randomisation until objective disease progression or death, whichever occurs first, assessed up to 56 months</time_frame>
    <description>Progression-free survival (PFS) is defined as time from date of randomisation until objective disease progression or death, whichever occurs first. Disease progression and its evaluation are defined based on RECIST 1.1. If neither event has been observed, then the patient is censored at the date of the last follow up examination.
Patients with new non-lung cancer malignancy must continue to be followed for progression of the original lung cancer.
Patients who discontinue treatment prior to documented disease progression, including those who initiate non-protocol therapy prior to progression, will be followed for disease progression and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response based on RECIST 1.1</measure>
    <time_frame>Response of the tumour is defined according to RECIST 1.1 criteria, assessed up to 56 months</time_frame>
    <description>For details to RECIST 1.1 criteria, see protocol appendix 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile of denosumab</measure>
    <time_frame>Assessed up to 56 months</time_frame>
    <description>Toxicity profile of denosumab: Adverse events classified according to NCI CTCAE V4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of potential predictive biomarkers for denosumab activity</measure>
    <time_frame>Assessed at baseline, week 7 and at progression (maximum of 56 months)</time_frame>
    <description>Collection of tumor material at randomisation (and highly desirable at progression) and collection of serum samples at baseline, at day 1 of cycles 3 (week 7) and at first progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Lung Cancer Non-small Cell Stage IV</condition>
  <arm_group>
    <arm_group_label>None, standard chemotherapy only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.
Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chemotherapy + Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.
Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).</description>
    <arm_group_label>Standard chemotherapy + Denosumab</arm_group_label>
    <other_name>XGEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None, standard chemotherapy only</intervention_name>
    <description>Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):
Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1</description>
    <arm_group_label>None, standard chemotherapy only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced stage IV non-small cell lung
             carcinoma (NSCLC), according to 7th TNM classification

          -  Age ≥ 18 years

          -  ECOG performance status 0-2

          -  Measurable or evaluable disease (according to RECIST 1.1 criteria) assessed within 28
             days from randomization.

          -  Availability of tumour tissue (as assessed by the local pathologist) for translational
             research:

          -  preferred: FFPE block from primary tumour or metastasis,

          -  alternatively: cell block

          -  if no block available: 10 freshly cut unstained slides.

          -  Adequate haematological function: neutrophils ≥ 1.5 ×109/L, platelets

             ≥ 100×109/L, and hemoglobin ≥ 9 g/dL

          -  Adequate liver function:

          -  ALT ≤ 3 × ULN ( ≤ 5 × ULN if liver metastasis are present)

          -  Total bilirubin &lt; 2 x ULN

          -  Adequate renal function: calculated renal creatinine clearance (CrCl) ≥ 30 mL/min
             (according to the formula of Cockroft-Gault)

          -  Life expectancy of at least 3 months

          -  Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
             before enrollment. Pregnancy test has to be repeated within 14 days before treatment
             start.

          -  All sexually active men and women of childbearing potential must use an effective
             contraceptive method during the study treatment and for a period of at least 6 months
             following the last administration of trial treatment

          -  Written Informed Consent must be signed and dated by the patient and the investigator
             prior to any trial-related intervention for

               1. Trial treatment

               2. Submission of biomaterial for central testing

        Exclusion Criteria:

          -  Patients with presence of documented sensitizing EGFR activating mutation or ALK
             rearrangements (screening following local standards is optional, but strongly
             encouraged in non-squamous histology)

          -  Patients with documented brain metastases (systematic screening of patients not
             mandatory; however, if the patient is symptomatic, brain metastases screening is
             recommended).

          -  Prior chemotherapy or molecular targeted therapy for metastatic disease.

        Exceptions:

          -  Neoadjuvant or adjuvant chemotherapy or radio-chemotherapy are allowed if terminated
             more than 6 months before registration.

          -  Previous radical radiotherapy without systemic treatment is allowed.

          -  One previous line of systemic immunotherapy by checkpoint inhibitors is allowed and
             needs to be documented

          -  Concomitant treatment with immune checkpoint inhibitors

          -  Any investigational agent(s) within 30 days prior to randomisation

          -  Concurrent bisphosphonate administration

          -  Oral/ dental conditions (by visual inspection):

          -  Prior history or current evidence of osteomyelitis / osteonecrosis of the jaw

          -  Active dental or jaw condition which requires oral surgery

          -  Planned invasive dental procedure for the course of the trial

          -  Non-healed dental or oral surgery

          -  Evidence of any medical condition which would impair the ability of the patient to
             participate in the trial or might preclude therapy with trial drugs (e.g. unstable or
             uncompensated respiratory, cardiac, hepatic or renal disease, active infection,
             uncontrolled diabetes mellitus; uncontrolled arterial hypertension ≥ 160/100 mmHg,
             history of myocardial infarction in the last 3 months)

          -  Documented active infection with Hepatitis B virus or Hepatitis C virus, known
             infection with human immunodeficiency virus (HIV)

          -  Known hypersensitivity to any of the components of the treatment

          -  Severe, uncorrected hypocalcaemia or hypercalcaemia:

          -  hypercalcaemia: total calcium &gt;3.1 mmol/l or corrected calcium (with albumin level) &gt;3
             mmol/l

          -  hypocalcaemia: total calcium &lt;2 mmol/l or corrected calcium (with albumin level) &lt; 1.9
             mmol/l

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition, including uncontrolled arterial hypertension
             (&gt;160/110) despite adequate medication which in the opinion of the investigator would
             not permit the patient to complete the trial or sign meaningful informed consent

          -  Women who are pregnant or breastfeeding

          -  Any concurrent malignancy other than adequately treated basal or squamous cell
             carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast
             carcinoma, or prostate cancer Gleason score &lt; 6. (Patients with a previous malignancy
             but without evidence of disease for ≥ 2 years will be allowed to enter the trial)

          -  Any previous exposure to denosumab, with the exception of a maximum of 2 previous
             doses of denosumab (Prolia®) more than 6 month before enrolment for osteoporosis
             treatment/prevention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solange Peters, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Trial Chair, CHUV Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary O'Brien, MD</last_name>
    <role>Study Chair</role>
    <affiliation>EORTC Trial Co-Chair, Royal Marden Hospital, Sutton, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Danson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>EORTC Trial Co-Chair, University of Sheffield, Sheffield, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf Stahel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trial Co-Chair, University Hospital of Zuerich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. Klinik für Innere Medizin V</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Wagner-Spital Department 1</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Wagner-Spital Department 2</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hosptial Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional De La Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>14000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternite Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire d`Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Beauvais</name>
      <address>
        <city>Beauvais Cedex</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitale de la Cavale Blanche - CHRU de BREST</name>
      <address>
        <city>Brest</city>
        <zip>29606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHPSO (Sie de Creil)</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Creteil</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Center Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Cluzeau</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHBS Lorient</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique-Hôitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l`Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHICAS</name>
      <address>
        <city>Sisteron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Villefranche-sur-Saône</name>
      <address>
        <city>Villefranche-sur-saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASKLEPIOS - Fachkliniken München - Gauting</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pius Hospital</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Miscordia University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Adelaide and Meath Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.G Moscati Hospital</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Paolo Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Car</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Golnik</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - L'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Castellón</name>
      <address>
        <city>Castelló</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Insular Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau Vilanova Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologiezentrum Berner Oberland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://www.etop-eu.org</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004 Jun 15;100(12):2613-21.</citation>
    <PMID>15197804</PMID>
  </reference>
  <reference>
    <citation>Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007 Aug;57(2):229-32. Epub 2007 Apr 23.</citation>
    <PMID>17451841</PMID>
  </reference>
  <reference>
    <citation>Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.</citation>
    <PMID>21343556</PMID>
  </reference>
  <reference>
    <citation>Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011 Feb 24;470(7335):548-53. doi: 10.1038/nature09707. Epub 2011 Feb 16.</citation>
    <PMID>21326202</PMID>
  </reference>
  <reference>
    <citation>Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012 Dec;7(12):1823-9. doi: 10.1097/JTO.0b013e31826aec2b.</citation>
    <PMID>23154554</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

